MALAT1 and lung carcinoma: These clinical studies clearly indicated that Oct4 positively correlates with NEAT1 and MALAT1 expression in lung cancer and that Oct4/NEAT1/MALAT1 co-overexpression is an independent factor for prediction of poor outcome in lung cancer patients.